Edition:
United States

Enzo Biochem Inc (ENZ.N)

ENZ.N on New York Stock Exchange

9.98USD
19 Oct 2017
Change (% chg)

$0.16 (+1.63%)
Prev Close
$9.82
Open
$9.79
Day's High
$9.99
Day's Low
$9.63
Volume
63,534
Avg. Vol
62,482
52-wk High
$12.04
52-wk Low
$5.80

Latest Key Developments (Source: Significant Developments)

BRIEF-Enzo Biochem Q4 non-gaap net income of $0.00 per share (Sept 27)
Thursday, 28 Sep 2017 11:02am EDT 

Corrects headline and third bullet to Q4 non-gaap net income of $0.00/share from non-gaap loss of $0.04/share:Enzo Biochem reports increase in revenues and profitable fourth quarter.Q4 revenue $28.2 million versus $26.6 million.Q4 non-gaap net income per share $0.00.  Full Article

Enzo Biochem Q4 non-gaap loss per share $0.04
Wednesday, 27 Sep 2017 04:05pm EDT 

Sept 27 (Reuters) - Enzo Biochem Inc :Enzo Biochem reports increase in revenues and profitable fourth quarter.Q4 revenue $28.2 million versus $26.6 million.Q4 non-gaap loss per share $0.04.  Full Article

Enzo Biochem files for mixed shelf of up to $150 million ‍​
Friday, 1 Sep 2017 04:43pm EDT 

Sept 1 (Reuters) - Enzo Biochem Inc :Files for mixed shelf of up to $150 million - SEC filing ‍​.  Full Article

Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott Laboratories ​
Wednesday, 16 Aug 2017 06:18am EDT 

Aug 16 (Reuters) - Enzo Biochem Inc ::Enzo Biochem says ‍a federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences, Inc. v. Abbott Laboratories - sec filing​.U.S. Court's order ‍denies summary judgment that U.S. Patent no. 8,097,405 is invalid for lack of written description.‍U.S. Court's order also granted summary judgment that U.S. Patent no. 8,097,405​ is invalid for lack of enablement.‍Enzo "disagrees" with court's decision, and is exploring options for review of decision​.  Full Article

Enzo Biochem says Q3 revenue up 2 pct to $27.1 mln
Thursday, 8 Jun 2017 04:10pm EDT 

June 8 (Reuters) - Enzo Biochem Inc :Q3 revenue rose 2 percent to $27.1 million.Q3 GAAP earnings per share $0.00.Enzo Biochem Inc qtrly total revenues increased to $27.1 million, a 2% increase.  Full Article

Enzo Biochem announces NY state health department approval of New Women’S Health Diagnostics
Thursday, 8 Jun 2017 04:00pm EDT 

June 8 (Reuters) - Enzo Biochem Inc :Enzo Biochem announces New York State Health Department approval of new Women’s Health Diagnostics.Approval for real-time PCR-based method for detection of neisseria gonorrhoeae, chlamydia trachomatis, trichomonas vaginalis in swab specimens.  Full Article

Enzo Biochem Qtrly loss per share $0.03
Thursday, 8 Dec 2016 04:05pm EST 

Enzo Biochem Inc : Qtrly loss per share $0.03 . Enzo Biochem reports improved first quarter results .Q1 revenue rose 4 percent to $26.3 million.  Full Article

Enzo Biochem announces New York State Health Department approval of new cardiac assay
Tuesday, 20 Sep 2016 12:24pm EDT 

Enzo Biochem Inc : Enzo Biochem announces New York State Health Department approval of new easily adaptable, cost effective cardiac assay .New York State Department of Health has granted conditional approval for use of Enzo Clinical Labs' PLAQPRO(tm) Lp-PLA2Assay.  Full Article

Enzo Biochem files for mixed shelf of up to $50 mln
Thursday, 1 Sep 2016 05:39pm EDT 

Enzo Biochem Inc : Files for mixed shelf of up to $50 million - SEC filing Source: (http://bit.ly/2cd7ICi) Further company coverage: [ENZ.N] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Enzo Biochem says Enzo Life Sciences reached settlement with Illumina that included payment of $21 mln to Enzo
Thursday, 7 Jul 2016 08:01am EDT 

Enzo Biochem Inc : Co's unit, Enzo Life Sciences, has reached and finalized a settlement with Illumina that included a payment of $21 million to enzo . Settlement resolving dispute between Enzo Life Sciences and Illumina impacts only one of 11 cases originally brought by enzo .Settlement related to action brought in delaware court by Enzo alleging infringement of patent.  Full Article

CORRECTED-BRIEF-Enzo Biochem Q4 non-gaap net income of $0.00 per share (Sept 27)

(Corrects headline and third bullet to Q4 non-gaap net income of $0.00/share from non-gaap loss of $0.04/share) Enzo Biochem Inc: